SurgiQuest closes $19M round

Orange, CT-based SurgiQuest has closed a $19 million round of financing from new and current investors. River Cities Capital Funds led the round, which also included Fletcher Spaght Ventures. Additional investments from CMEA Ventures, California Technology Ventures, Aphelion Medical Fund and other existing SurgiQuest investors completed the round. 

SurgiQuest, which was founded in May 2006, develops, manufactures and markets innovative access technology for minimally invasive surgery. Its AirSeal access system aids access to the abdominal cavity during minimally invasive surgery. Unlike conventional insufflation and trocar systems, the company's platform assures stable pneumoperitoneum, continuously evacuates smoke and plume when energized medical devices such as electrocautery, laser or ultrasound are used, and provides valve-free access to the abdominal cavity during both laparoscopic and robotic surgical procedures.

The company plans to use the money to respond to increasing demand for its products and drive commercialization initiatives worldwide.

- see more from the SurgiQuest release

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.